ND SB2096

Amends North Dakota controlled substance schedules by adding new synthetic drugs and fentanyl derivatives to Schedule I, including U47700, MT-45, AH7921, and a broad category of fentanyl derivatives with specific chemical structure modifications.

Expands Schedule I hallucinogenic substances list to include additional synthetic cannabinoids, indole-based compounds, and substituted phenethylamines (such as 2C-series drugs and various NBOMe compounds).

Adds substituted tryptamines and other emerging drugs of abuse to Schedule I, including specific compounds like TFMPP, methoxetamine, and salvia divinorum derivatives.

Updates Schedule II, III, IV, and V by adding new synthetic cathinones (bath salts), brivaracetam, and modifying depressant and stimulant listings to reflect current drug trends.

Declares the act an emergency measure, indicating urgent need to address emerging synthetic drug threats in North Dakota.